1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Beijing SL Pharmaceutical Co., Ltd.

Beijing SL Pharmaceutical Co., Ltd.

002038.SZ
Beijing SL Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
6.28
CNY
+0.45
- -
6.45BMarket Cap
Beijing SL Pharmaceutical Co., Ltd.
002038.SZ
(Shenzhen Stock Exchange)

Recent

price

6.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.45
0.61
0.98
1.13
1.21
1.13
0.98
1.21
3.16
1.96
1.1
1.17
1.03
1
0.62
0.61
0.5
Revenue per Share
0.27
0.51
0.47
0.56
0.68
0.56
0.44
0.52
0.83
0.47
0.36
0.41
0.23
0.41
-0.07
-0.34
0.02
Basic EPS, GAAP
0.19
0.15
0.15
0.23
0.31
0.37
0.23
0.15
0.38
0.38
0.16
0.22
0.22
0.24
-0.12
0.06
-0.36
Free Cash Flow per Basic Share
0.05
0.06
0.07
0.09
0.09
0.13
0.13
0.13
0.5
0.2
0.2
0.1
0.1
0.1
0.15
0.02
- -
Dividend per Share
1.04
1.46
1.81
2.21
2.75
3.12
3.38
3.71
5.81
4.07
4.28
4.49
4.7
5.02
4.61
4.42
4.35
Book Value per Share
1.12
1.57
1.95
2.33
2.9
3.3
3.57
3.83
5.6
4.04
4.22
4.29
4.42
4.59
4.14
3.97
3.93
Tangible Book Value per Share
1,020
1,024
1,028
1,031
1,027
1,027
1,027
1,027
685
1,036
1,013
1,039
1,019
1,016
1,058
1,021
1,149
Basic Weighted Avg Shares
458
623
1,007
1,162
1,243
1,157
1,010
1,242
2,167
2,030
1,113
1,215
1,050
1,018
660
624
573
Sales/Revenue/Turnover
56.29
58.77
51.43
52.32
58.2
49.87
45.79
31.15
30.87
24.82
15.22
21
17.33
24.56
6.63
-0.42
-12.42
Operating Margin (%)
14
18
20
23
31
33
34
37
56
77
89
100
114
145
153
167
- -
Depreciation Expense
273
523
481
577
695
575
452
534
571
487
365
426
234
417
-74
-347
17
Net Income, GAAP
13.51
13.25
14.34
15.09
13.71
13.69
15.17
15.08
16.12
14.51
12.43
7.97
11.96
10.74
- -
- -
20.01
Effective Tax Rate (%)
59.57
84.03
47.77
49.7
55.92
49.72
44.77
42.96
26.36
23.98
32.78
35.06
22.32
40.92
-11.21
-55.67
3.03
Profit Margin (%)
728
1,144
1,404
1,622
2,167
2,473
2,624
2,803
2,363
2,533
1,892
1,973
1,709
2,267
2,199
1,364
2,362
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
- -
- -
- -
- -
- -
LT Debt
1,211
1,686
2,112
2,589
3,181
3,613
3,930
4,299
4,543
4,821
4,985
5,326
5,479
5,810
5,581
5,189
5,701
Total Equity
20.13
21.72
23.09
21.66
21.41
14.55
10.36
7.95
12.65
9.23
3.05
4.61
3.02
4.05
- -
- -
- -
Return on Invested Capital (%)
26.97
39.03
27.05
27.5
26.71
18.26
13.09
14.23
14.33
12.01
8.58
9.54
5.08
8.44
- -
- -
-1.56
Return on Capital (%)
28.55
40.95
28.64
27.87
27.24
19.09
13.54
14.64
14.66
11.89
8.53
9.47
4.96
8.42
-1.48
-7.4
0.34
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,027
1,027
1,027
Market Capitalization
7,484
7,608
8,148

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,489
2,562
2,563
Cash, Cash Equivalents & STI
893
785
887
Accounts Receivable, Net
103
100
86
Inventories
246
403
415
Total Current Liabilities
289
334
200
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.81%
0.96%
-7.03%
Free Cash Flow
-26.56%
-50.96%
-153.07%
Net Income, GAAP
26.44%
60.12%
368.77%
Sales/Revenue/Turnover
-1.49%
-9.63%
-5.57%
Total Cash Common Dividend
- -
- -
-88.39%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
245
147
148
120
660
2025
169
136
165
- -
624
2026
137
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
- -
- -
- -
-0.07
2025
0.04
- -
- -
- -
-0.34
2026
-0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.15
2025
- -
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -
Similar Companies
Haleon plc (HLN)
Chong Kun Dang Holdings Corp. (001630.KS)
Luff Enterprises Ltd. (LUFF.CN)
Haleon plc (HLN.L)
RedHill Biopharma Ltd. (RDHL)
Canntab Therapeutics Limited (PILL.CN)
Business
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) develops, manufactures, and markets genetic engineering drugs, biological products, biochemical drugs, chemical preparations, and related pharmaceuticals primarily for hematology, oncology, immunology, cardiovascular, anti-infective, diabetes, digestive, neurological, musculoskeletal, anti-allergic, urinary, and peptide hormone therapeutic areas. Core products include recombinant human granulocyte colony-stimulating factor (rhG-CSF) injections; interleukin-2 (rhIL-2), interleukin-11 (rhIL-11), and basic fibroblast growth factor (rh-bFGF) injections; biochemicals such as cytidine disodium triphosphate, calcium folinate, salmon calcitonin, coenzyme complex, netilmicin sulfate, matrine, and cyclosporin injections; chemical drugs encompassing tablets and capsules like desloratadine orally-disintegrating tablets, zaleplon capsules, naftopidil tablets, tropisetron hydrochloride capsules, telmisartan tablets, metformin hydrochloride/glyburide tablets, stavudine capsules, temozolomide, paclitaxel, gemcitabine, asparaginase; and dosage forms such as small-volume injections, freeze-dried powder injections, granules, hard capsules, soft gels, nasal preparations, oral liquids, aerosols, sprays, and health-care foods including Hongxin Capsule. The company operates production facilities and sales networks across China, with offices in Beijing, Liaoning, and Henan provinces, targeting domestic markets and select overseas distribution. Founded in 1994 and headquartered at 4th Floor, Building 1, Bitongyuan, No. 69 Fushi Road, Haidian District, Beijing, China, it maintains approximately 889 employees and holds 61 patents, including three national-level new drugs with independent intellectual property rights. In recent developments as of November 2025, the company advances a GLP-1 long-acting product toward regulatory submission by compiling necessary documentation, reflecting strategic expansion into metabolic therapies amid China's innovative drug boom.